The Regeneron Antibody Cocktail offers COVID Protection
April 13, 2021 – People living with someone with COVID-19 appear to have strong protection against infections when they are given Regeneron antibody cocktails, a new study shows.
The findings suggest that the worst results are avoided coronavirus given the infection early enough, the cocktail could prevent people from getting sick as soon as possible, the company said on Monday.
“While more than 60,000 Americans continue to be diagnosed with COVID-19 every day, the REGEN-COV antibody cocktail will help provide immediate protection to unvaccinated individuals who have been exposed to the virus, and we are also working to understand its potential to provide ongoing protection for immunocompromised patients vaccines“Dr. George Yancopoulos, president and scientific director of Regeneron, said in a statement.
In his statement, Regeneron said he would call on the U.S. Food and Drug Administration to expand the use of emergency medication permits – to high-risk people who already have COVID-19 but are not hospitalized – to be given for prevention purposes in “appropriate populations.”
There are “a large number of people” in the United States and around the world who may be eligible to receive these drugs for prevention purposes, Dr. Myron Cohen, a researcher at the University of North Carolina, told The New York Times. He directs monoclonal antibody efforts for the Covid Prevention Network, an initiative sponsored by the U.S. National Institutes of Health that helped oversee the Regeneron trial.
“Not everyone will take it vaccine, whatever we do, and not everyone will respond to a vaccine, ”Cohen said.
New data on Regeneron’s antibody cocktail clinical trial in the previous four days more than 1,500 people living in the same house as someone who had tested positive for the virus were registered. Those who received an injection of the drug Regeneron were 81 percent less likely to use COVID-19 compared to volunteers with the disease. placebo, the company said.
Dr. Rajesh Gandhi, an infectious disease doctor at Massachusetts General Hospital who did not participate in the study, told the Times that the data is “promising” for people who have not been vaccinated. But he noted that the types of patients who would be required to determine whether the drug should be used preventively for immunocompromised patients were not included in the test. “I would say we don’t know yet,” Gandhi said.
Regeneron cocktail, a combination of two drugs designed to naturally mimic the antibodies produced immune system defends the virus, which was given to President Donald Trump after he fell ill with COVID-19 last fall.
The treatment received an emergency permit last November. It is used by doctors, as well as another antibody cocktail by Eli Lilly, for high-risk COVID-19 patients to protect against serious illness and hospitalization.
But many hospitals and clinics have not given priority to treatments because they require a lot of time and are difficult to administer, especially because they need to be done through the veins. Regeneron wants to ask the FDA to allow the drug to be given by injection, as in the latest study, which would allow it to be delivered faster and easier.